Skip to main content

IFNAR1 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 7 bp deletion in exon 1 and Insertion of the selection cassette in exon 1.

Be the first to review this product! Submit a review

Images

Sanger Sequencing - Human IFNAR1 (Interferon alpha/beta receptor 1) knockout HeLa cell line (AB261782), expandable thumbnail
  • Sanger Sequencing - Human IFNAR1 (Interferon alpha/beta receptor 1) knockout HeLa cell line (AB261782), expandable thumbnail
  • Western blot - Human IFNAR1 (Interferon alpha/beta receptor 1) knockout HeLa cell line (AB261782), expandable thumbnail

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

Knockout validation

Sanger Sequencing, Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, 7 bp deletion in exon 1 and Insertion of the selection cassette in exon 1

Alternative names

Recommended products

IFNAR1 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 7 bp deletion in exon 1 and Insertion of the selection cassette in exon 1.

Key facts

Cell type

HeLa

Form

Liquid

Mutation description

Knockout achieved by using CRISPR/Cas9, 7 bp deletion in exon 1 and Insertion of the selection cassette in exon 1

Disease

Adenocarcinoma

Concentration
Loading...

Properties

Gene name

IFNAR1

Gene editing type

Knockout

Gene editing method

CRISPR technology

Knockout validation

Sanger Sequencing, Western blot

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines

  • All seeding densities should be based on cell counts gained by established methods.

  • A guide seeding density of 2x104 cells/cm2 is recommended.

  • Cells should be passaged when they have achieved 80-90% confluence.

Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Storage

Shipped at conditions

Dry Ice

Appropriate short-term storage conditions

-196°C

Appropriate long-term storage conditions

-196°C

Notes

Recommended control: Human wild-type HeLa cell line (Human wild-type HeLa cell line ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

Interferon alpha/beta receptor 1 also known as IFNAR1 is an important component of the interferon receptor complex which includes the interferon beta receptor (IFNBR) and the broader class of interferon receptors. IFNAR1 is a transmembrane protein with a molecular mass of approximately 100 kDa. It shows expression in various tissues but predominantly in cells of the immune system. This expression pattern enables IFNAR1 to play a central role in mediating responses to interferon alpha and beta which are cytokines important in the immune response.

Biological function summary

IFNAR1 partners with interferon alpha receptor 2 (IFNAR2) to form a functional receptor complex. This complex binds interferons alpha and beta triggering signal transduction cascades vital for antiviral defense. Through this interaction IFNAR1 facilitates cellular immune responses including the activation of antiviral genes and modulation of cell proliferation. IFNAR1's role extends beyond immediate immune response influencing processes like cell differentiation and apoptosis.

Pathways

IFNAR1 is a participant in the JAK-STAT signaling pathway a significant pathway for transmitting cytokine signals. Upon interferon binding it activates the associated Janus kinases (JAKs) which in turn phosphorylate signal transducers and activators of transcription (STATs) specifically STAT1 and STAT2. This chain of events results in the transcription of interferon-stimulated genes that provide antiviral defenses and promote immune regulation. IFNAR1's engagement in these pathways makes it an integral part of immune system communication.

Associated diseases and disorders

IFNAR1 associates strongly with autoimmune diseases and viral infections. In lupus an autoimmune disorder dysregulation in interferon signaling involving IFNAR1 contributes to disease progression. Moreover in viral infections like hepatitis C the response of IFNAR1 to interferon therapies can influence treatment outcomes. Understanding these connections facilitates therapeutic strategies that target interferon pathways for improved disease management.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

3 product images

  • Sanger Sequencing - Human IFNAR1 (Interferon alpha/beta receptor 1) knockout HeLa cell line (ab261782), expandable thumbnail

    Sanger Sequencing - Human IFNAR1 (Interferon alpha/beta receptor 1) knockout HeLa cell line (ab261782)

    Allele-2: Insertion of the selection cassette in exon 1.

  • Sanger Sequencing - Human IFNAR1 (Interferon alpha/beta receptor 1) knockout HeLa cell line (ab261782), expandable thumbnail

    Sanger Sequencing - Human IFNAR1 (Interferon alpha/beta receptor 1) knockout HeLa cell line (ab261782)

    Allele-1: 7 bp deletion in exon 1.

  • Western blot - Human IFNAR1 (Interferon alpha/beta receptor 1) knockout HeLa cell line (ab261782), expandable thumbnail

    Western blot - Human IFNAR1 (Interferon alpha/beta receptor 1) knockout HeLa cell line (ab261782)

    Western blot: Anti-IFNAR1 antibody [EPR6244] (Anti-Interferon alpha/beta receptor 1 antibody [EPR6244] ab124764) staining at 1/1000 dilution, shown in green; Mouse anti-CANX [CANX/1543] (Anti-Calnexin antibody [CANX/1543] ab238078) loading control staining at 1/20000 dilution, shown in red. In Western blot, Anti-Interferon alpha/beta receptor 1 antibody [EPR6244] ab124764 was shown to bind specifically to IFNAR1. A band was observed at 116 kDa in wild-type HeLa cell lysates with no signal observed at this size in IFNAR1 knockout cell line. To generate this image, wild-type and IFNAR1 knockout HeLa cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution.

    All lanes: Western blot - Anti-Interferon alpha/beta receptor 1 antibody [EPR6244] (Anti-Interferon alpha/beta receptor 1 antibody [EPR6244] ab124764) at 1/1000 dilution

    Lane 1: Wild-type HeLa cell lysate at 20 µg

    Lane 2: IFNAR1 knockout HeLa cell lysate at 20 µg

    Secondary

    All lanes: Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution

    Performed under reducing conditions.

    Predicted band size: 64 kDa

    Observed band size: 116 kDa

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com